Skip to main content
Premium Trial:

Request an Annual Quote

Genetron Health Receives CE Mark for Lung Cancer Sequencing Assay

NEW YORK – Genetron Health said Tuesday that it has received the CE mark for its eight-gene lung cancer sequencing assay.

The test kit, which has also been approved by China’s National Medical Products Administration, uses a technology called One-Step Seq, which allows for a single-reaction library construction process, minimizing manual operation and reducing the chance of contamination.

The assay covers mutations in EGFR, BRAF, KRAS, HER2, and PIK3CA, translocations of ALK and ROS1, and MET exon 14 skipping, and is compatible with the Genetron S5 sequencing platform.

Genetron CEO Sizhen Wang said in a statement that this platform-assay combination, along with added bioinformatic support, provides a highly automated end-to-end solution for hospitals and clinical laboratories that prefer to run next-gen sequencing testing on their own rather than send samples to an outside lab.

"We believe that this offers a significant operational advantage for our customers outside China," Wang added.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more